ArticleJournal of breast imaging2026
Screening Breast MRI and Genetic Testing Utilization in High-risk Population: Analysis of National Health Interview Survey.
Article in Journal of breast imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveFor individuals at increased risk of breast cancer, additional tests, such as screening breast MRI and genetic testing, are recommended. We assessed the utilization of screening breast MRI and genetic testing among high-risk individuals and identified associated patient factors.
methodsThis retrospective, cross-sectional study used 2023 National Health Interview Survey data. Women aged 25 or older with at least 1 first-degree relative diagnosed with breast cancer before age 50 were included. A survey weight was applied to generate weighted samples representing national estimates. Multivariable logistic regression analysis was used to identify factors associated with screening breast MRI, genetic test discussions, and genetic test completion.
resultsThe weighted sample included 6 851 757 women (unweighted n = 920) (mean age, 60.2; 3.1% [199 883/6 486 458] Asian, 14.4% [932 502/6 486 458] Black, 78.1% [5 063 194/6 486 458] White, and 4.4% [290 879/6 486 458] other races). Overall, 12.5% (855 463/6 851 757) were of Hispanic ethnicity. Screening MRI use was reported by 7.9% (506 672/6 417 453) , while 28.8% (1 963 524/6 822 303) discussed and 17.7% (1 209 406/6 830 229) completed genetic testing. Having 2 or more first-degree relatives with breast cancer increased the likelihood of screening MRI (odds ratio [OR], 2.94; 95% CI, 1.56-5.54) and genetic testing completion (OR, 2.74; 95% CI, 1.68-4.48). The odds of discussing genetic testing were lower for Black individuals (OR, 0.43; 95% CI, 0.20-0.91) and those with Medicaid or no insurance (OR, 0.45; 95% CI, 0.23-0.87). Concern about medical bills was associated with lower odds of genetic testing completion (OR, 0.54; 95% CI, 0.33-0.90).
conclusionsScreening breast MRI and genetic testing are underutilized among high-risk women. Expanding insurance coverage and provider education may help increase uptake of recommended screening practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.